Moneyta · stock research · no sign-up needed
MRNA
FollowFigures below come straight from SEC filings: every number is the company's own, on the record.
Revenue (Q2 FY2026)
$145M
+34.3% y/y
Net income (Q2 FY2026)
-$782M
as filed with the SEC
Institutions holding
801
+60 last quarter
Overview · Moderna, Inc.
Moderna, Inc., a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, flu, respiratory syncytial virus, Endemic HCoV, and hMPV+PIV3 vaccines; latent vaccines comp…
Management team
- Dr. Melanie Ivarsson M.B.A., Ph.D. · Chief Development OfficerFind on LinkedIn
- Ms. Tracey Franklin · Chief Human Resources OfficerFind on LinkedIn
- Mr. Brad Miller · Chief Information OfficerFind on LinkedIn
- Dr. Jerh Collins Ph.D. · Chief Technical Operations & Quality OfficerFind on LinkedIn
Start free to see the full management team.
Links open LinkedIn searches, not verified profiles. Team data from our market-data vendor's company profile.
What history says when its signals fire
Every signal Moneyta surfaces carries its full base-rate history: how often it beat the index, and how often it didn't. See the evidence
The desk's Snapshot
3 of 15 open to everyone · members see allRead the full desk report on MRNA
Seven analysts, the debate, the risk review, every claim cited. And the same for every name you hold.
Free plan, no credit card required. Silver opens the full report, $19.99 a month. AI-written · every claim cites a source · Insight, not advice.
The full desk report
Seven AI analysts read the filings and argue both sides. What survives, with every claim cited, for members.
Who holds it, who's buying Gold
Full holder table, quarter-over-quarter flows, insider transactions, and the conviction screen.
Largest holder
Net flow last quarter
Insider buys, 90d
Further reading
Source: SEC EDGAR (XBRL company facts, form 13F-HR). Educational analysis of published data: insight, not advice.